Search results
MacroGenics to Participate in Upcoming Investor Conferences
Morningstar· 4 days agoROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal ...
Pipeline Moves: Phase III completion for Corcept’s relaorilant
Clinical Trials Arena via Yahoo Finance· 4 days agoAlso, Lyvgen’s monoclonal antibody (mAb) dalnicastobart has seen its transition prospects increase...
Nipocalimab's Unique Mechanism Gets Second Chance in RA
Medscape· 5 days agoThe IRIS-RA study of the investigational monoclonal antibody drug nipocalimab in patients with...
GSK to divest remaining 4.2% stake in Haleon
Pharmaceutical Technology via Yahoo Finance· 10 hours agoThe agreement comprises an upfront payment of $1bn and $400m in regulatory milestone payments. Through the deal, GSK will gain access to AIO-001, a...
Uniquity Bio launches to focus on immunology and inflammation
Pharmaceutical Technology via Yahoo Finance· 1 day agoA monoclonal antibody, solrikitug targets thymic stromal lymphopoietin. It will treat critical...
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
The Wall Street Journal· 7 days agoThe company’s trial was evaluating the cancer-drug Opdivo and concurrent chemoradiotherapy, followed...
Sanofi boosts French biomanufacturing with €1 billion investment
Investing.com· 5 days agoSanofi (EPA: SASY ) (NASDAQ: SNY ), a global biopharmaceutical company, announced today a...
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building...
WDTN-TV 2 Dayton· 4 days agoThis represents another milestone in the Company's pursuit of a functional cure for HBV, following the Breakthrough Therapy Designation granted for BRII-179, a recombinant protein-based HBV ...
Critics Say FDA's Use of Surrogate Markers Falling Short
Medscape· 13 hours agoAs the FDA's use of surrogate endpoints in the drug approval process is increasing, researchers are...
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis -...
Benzinga· 2 days agoCelldex Therapeutics, Inc. CLDX today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is ...
